Exonate

#Biotech #Exonate #Ophthalmology

Eye disease specialist Exonate appoints Hellebø as CEO 

Biotechnology company Exonate has appointed Olav Hellebø as Chief Executive Officer.  Exonate, which specialises in small-molecule therapeutics for patients with retinal vascular diseases, says Hellebø will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of… Read More

#News

Patient receiving eye drops
#Exonate #Ophthalmology #Phase II trial

Plans for Phase IIb trial of EXN407 for diabetic eye disease

Exonate has announced plans to initiate a Phase IIb clinical trial for its lead candidate, EXN407. The Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease (CLEAR-DE) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Collaboration #Exonate #Exploristics #Ophthalmology

Partners enhance trial design using cloud-based simulation

Exploristics and Exonate have announced the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease. The collaboration has supported ongoing development of Exonate’s lead candidate, EXN407, following a recent successful Phase Ib/IIa study in November. Read More

#News

Eye health ophthalmology
#Clinical trials #Diabetes #Exonate #Eye health #mRNA #Ophthalmology #Small molecules

Trial in diabetic macular oedema successfully completed  

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study.   During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity. Exonate… Read More

#News